Colorectal cancer management

Key points
- Colorectal cancer symptoms and signs are, in general, nonspecific.
- Once colorectal cancer has been diagnosed, preoperative evaluation must be performed to assess the best approach for treatment.
- Unfortunately, the majority of patients with colorectal cancer are diagnosed because they have symptoms or signs.
- The most common presenting symptom of colon cancer is vague abdominal pain.
CLINICAL PRESENTATION
Colorectal cancer symptoms and signs are, in general, nonspecific. Unfortunately, the majority of patients with colorectal cancer are diagnosed because they have symptoms or signs. The most common presenting symptom of colon cancer is vague abdominal pain. In the rectum, patients most frequently complain of blood in the stools. Any patient who presents with either blood in the stools or rectal bleeding should be worked up. Rectal bleeding should not be attributed to hemorrhoids unless a complete evaluation has been performed.
Most of the time, right-sided tumors present less symptomatology than left-sided or rectal tumors. Commonly patients with right-sided tumors present with anemia. Left-sided or rectal cancer patients most commonly present with change in bowel habits or blood in the stools. Other symptoms of colorectal cancer include nausea, vomiting, bloating, diarrhea, tenesmus, constipation, and weight loss.
Partial or complete bowel obstructions as well as perforation, whether localized or free into the abdomen, are not uncommon presentations of colorectal cancer.
Both of these situations carry a worse prognosis. In two prospective randomized trials of Dukes' B and C colorectal cancer, the National Surgical Adjuvant Breast and Bowel Project (NSABP) reported that patients with bowel obstruction were at greater risk of treatment failure than those without obstruction. These investigators also reported that the effect of bowel obstruction was influenced by the location of the tumor. The occurrence of bowel obstruction in the right colon was associated with a significantly diminished disease-free survival, whereas obstruction in the left colon demonstrated no such effect.
Perforation occurs most commonly at the site of the tumor itself or in the bowel proximal to the obstruction. These patients can present with localized peritonitis or diffuse peritonitis. In addition, they can be dehydrated, septic, and with electrolyte imbalances. All these factors add to the morbidity of emergent surgery. Perforation can result in adherence to adjacent organs or fistula formation. Concomitant perforation is not uncommon in patients with obstruction. The principles of surgical management are the same as with patients with obstructing carcinomas. Ideally, an attempt at resection should be performed. However, there are times that the inflammatory reaction or patient's condition precludes resection, and thus, it is safer to divert the patient and drain the perforation rather than embark on an unsafe surgical procedure. A downside of this approach is seeding of the drainage tract. The tract must be removed en bloc with the tumor at the time of definitive resection. This potential downside must be weighed with the complications of an unsafe resection through unclear planes in a potentially unstable patient.
Adherence to adjacent organs or fistula formation may be another presentation of colorectal cancer. Any intra-abdominal organ can be adhered to the tumor. These adhesions are malignant in nature in over 40% of the cases. Because clinically it cannot be determined whether the adhesions are inflammatory of malignant in nature, an en bloc resection must be performed. Performing less than an en bloc resection will increase recurrence rate and decrease survival.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsImmune-boosting colorectal cancer drug shows promise
New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer. The findings confirm the biological…
6 July 2013
NewsBiomarker identification may lead to new noninvasive test for colorectal cancer detection
The average 5-year survival for colorectal cancer (CRC) is less than 10% if metastasis occurs, but can reach 90% if detected early. A new non-invasive test has been developed that measures methylation of the SDC2 gene…
7 June 2013
NewsSleep duration associated with higher colorectal cancer risk
A new study is the first to report a significant positive association between long sleep duration and the development of colorectal cancer , especially among individuals who are overweight or snore regularly. The…


